U.S. Biodefense Market (2024 - 2030) Size, Share & Trends Analysis Report By Product (Anthrax, Small Pox, Botulism, Radiation/nuclear), And Segment Forecasts
- Report Summary
- Table of Contents
- Segmentation
- Methodology
- Download FREE Sample
-
Download Sample Report
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.3. Competitive Insights
Chapter 3. U.S. Biodefense Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Biodefense Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Biodefense Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Biodefense Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Anthrax
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.2. Smallpox
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.3. Botulism
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.4. Radiation/nuclear
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
4.4.5. Others
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
Chapter 5. Competitive Landscape
5.1. Recent Developments & Impact Analysis, By Key Market Participants
5.2. Company/Competition Categorization
5.3. Vendor Landscape
5.3.1. List of key distributors and channel partners
5.3.2. Key customers
5.3.3. Key company heat map analysis, 2023
5.4. Company Profiles
5.4.1. XOMA Corporation
5.4.1.1. Company overview
5.4.1.2. Financial performance
5.4.1.3. Product benchmarking
5.4.1.4. Strategic initiatives
5.4.2. Altimmune, Inc.
5.4.2.1. Company overview
5.4.2.2. Financial performance
5.4.2.3. Product benchmarking
5.4.2.4. Strategic initiatives
5.4.3. EMERGENT
5.4.3.1. Company overview
5.4.3.2. Financial performance
5.4.3.3. Product benchmarking
5.4.3.4. Strategic initiatives
5.4.4. Dynavax Technologies
5.4.4.1. Company overview
5.4.4.2. Financial performance
5.4.4.3. Product benchmarking
5.4.4.4. Strategic initiatives
5.4.5. SIGA Technologies
5.4.5.1. Company overview
5.4.5.2. Financial performance
5.4.5.3. Product benchmarking
5.4.5.4. Strategic initiatives
5.4.6. Elusys Therapeutics, Inc.
5.4.6.1. Company overview
5.4.6.2. Financial performance
5.4.6.3. Product benchmarking
5.4.6.4. Strategic initiatives
5.4.7. Ichor Medical Systems
5.4.7.1. Company overview
5.4.7.2. Financial performance
5.4.7.3. Product benchmarking
5.4.7.4. Strategic initiatives
5.4.8. Dynport Vaccine Company (General Dynamics Information Technology, Inc.)
5.4.8.1. Company overview
5.4.8.2. Financial performance
5.4.8.3. Product benchmarking
5.4.8.4. Strategic initiatives
5.4.9. Cleveland Biolabs
5.4.9.1. Company overview
5.4.9.2. Financial performance
5.4.9.3. Product benchmarking
5.4.9.4. Strategic initiatives
5.4.10. Bavarian Nordic
5.4.10.1. Company overview
5.4.10.2. Financial performance
5.4.10.3. Product benchmarking
5.4.10.4. Strategic initiatives
5.4.11. Ology Bioservices, Inc.
5.4.11.1. Company overview
5.4.11.2. Financial performance
5.4.11.3. Product benchmarking
5.4.11.4. Strategic initiatives
5.4.12. Alnylam Pharmaceuticals, Inc.
5.4.12.1. Company overview
5.4.12.2. Financial performance
5.4.12.3. Product benchmarking
5.4.12.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S. biodefense market, by product, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. biodefense market: market outlook
Fig. 9 Biodefense competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. biodefense market driver impact
Fig. 14 U.S. biodefense market restraint impact
Fig. 15 U.S. biodefense market: Product movement analysis
Fig. 16 U.S. biodefense market: Product outlook and key takeaways
Fig. 17 Anthrax market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 18 Smallpox estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 19 Botulism market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 20 Radiation/nuclear estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 21 Others estimates and forecasts, 2018 - 2030 (USD Billion)
Get Free Sample Report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
